This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX)
by Zacks Equity Research
Regenxbio (RGNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 95.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -31.75% and 49.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -0.66% and 37.92%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of 6.76% and 12.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 3.85% and 28.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Intra-Cellular Therapies (ITCI) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -12.90% and 10.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -9.72% and 25.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Regenxbio (RGNX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -25.58% and 21.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Regenxbio (RGNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 102%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 101.7% upside potential for Regenxbio (RGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Regenxbio (RGNX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of 55.84% and 29.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare (ACHC) Lags Q4 Earnings Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of -1.47% and 1.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Soars 5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Kodiak (KOD) Completes Enrolling Patients in Retina-Based Studies
by Zacks Equity Research
Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its VEGF inhibitor in patients with DME.
Sarepta's (SRPT) DMD Gene Therapy Study Data Fails to Impress
by Zacks Equity Research
Sarepta's (SRPT) DMD gene therapy candidate achieves statistically significant improvement in patients but the data fails to meet market expectations. Stock down.
Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate
by Zacks Equity Research
Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.
4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio
by Zacks Equity Research
Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.
REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status
by Zacks Equity Research
REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.
Regenxbio (RGNX)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -57.47% and -37.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Can Regenxbio (RGNX) Climb 77% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 77.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win
by Kinjel Shah
AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.